Clinical Trials Directory

Trials / Unknown

UnknownNCT01122225

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
Université Victor Segalen Bordeaux 2 · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels. The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

Detailed description

Primary Outcome Measures: To correlate elevated serum NGAL with the diagnosis of intrinsic acute kidney injury in septic shock Secondary Outcome Measures : To compare serum NGAL with serum creatinine, serum urea and urine output in septic AKI Death within the intensive care unit Death from all causes at 28 days after inclusion

Conditions

Timeline

Start date
2009-07-01
Primary completion
2010-05-01
Completion
2010-06-01
First posted
2010-05-13
Last updated
2010-05-31

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01122225. Inclusion in this directory is not an endorsement.